- Status:
- Red
- Decision Date:
- January 2018
Comments
RED1,2,3,8: NICE TA496 - for use in combination with an aromatase inhibitor for previously untreated hormone receptor-positive, HER2 negative, locally advanced or metastatic breast cancer.
RED1,2,3,8: NICE TA593 - treating hormone receptor-positive, HER2-negative, advanced breast cancer (Decision date - September 2019)
RED1,2,3,8: NICE TA687 - with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer. Replaces NICE TA593 (Decision date - April 2021)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again